Sareum to Present at BioTrinity 2015

RNS Number : 7626M

Sareum Holdings PLC

12 May 2015

 

12 May 2015

Sareum Holdings PLC

("Sareum" or the "Company")

Sareum to Present at BioTrinity 2015

Sareum Holdings plc(AIM:SAR), the specialist cancer drug discovery and development business, is pleased to announce that CEO Dr Tim Mitchell will make a Company presentation at BioTrinity 2015 on May 12.

Dr Mitchell's presentation is scheduled for 15.30pm in the Oncology track. It will describe Sareum's research pipeline, including the CHK1 cancer programme which is expected to file for clinical trials approval later this year.

BioTrinity is Europe's leading Biopartnering and Investment Conference, and is being held on 11-13 May at the Novotel London West.

Dr Tim Mitchell, CEO of Sareum, commented: "This exciting event offers us an ideal opportunity to present our latest developments to both investors and potential licence partners."

Jon Rees, CEO of OBN, said: "BioTrinity has become the "must attend" life sciences conference for emerging European companies, investors and partners. We are excited to be hosting what we believe would be the great business development opportunity of 2015. This announcement from Sareum confirms that this is an event that deal and decision makers cannot afford to miss."

For further information, please contact:

Sareum Holdings PLC
Tim Mitchell	Tel: [phone]
WH Ireland Limited (Nominated Adviser and Co-Broker)
Chris Fielding / Nick Prowting	Tel: [phone]
Hybridan LLP (Co-Broker)
Claire Noyce / William Lynne	Tel: [phone]
The Communications Portfolio (Public Relations)
Ariane Comstive [e-mail]	Tel: [phone]

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

About BioTrinity

Founded and produced by OBN, BioTrinity is now in its ninth year. BioTrinity has grown rapidly over recent years, and is now located in London to accommodate increased interest. More than 1000 senior executives and decision makers from emerging and established companies across the life sciences sector and investment firms are expected to meet one-on-one, attend panel discussions , company showcases and workshops, or browse the company showcases, seeking out their next deals.

Contact: Citigate Dewe Rogerson Sylvie Berrebi Tel: [phone] Email:  Sylvie.berrebi @citigatedr.co.uk

About OBN

OBN is the Membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our 370-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland and benefit from our networking, partnering, purchasing, advising and advocacy activities.  OBN is best known for its delivery of BioTrinity (May 11-13), Europe's leading life sciences investment and biopartnering conference.

Further information about OBN's tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN's website www.obn.org.uk.

 

END

 

 

NRAVFLBFEEFEBBV